QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 top-performing-industry-etfs-in-june-software-leads-returns-chipmakers-attract-most-inflows

June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while ut...

 avidity-biosciences-and-cleanspark-were-among-the-10-biggest-mid-cap-stock-gainers-last-week-june-9-june-15-are-these-in-your-portfolio

Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, Cle...

 reported-earlier-avidity-biosciences-prices-4009m-public-offering-of-1055m-common-shares-at-38share

All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before...

 b-of-a-securities-maintains-buy-on-avidity-biosciences-raises-price-target-to-45

B of A Securities analyst Geoff Meacham maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target fr...

 needham-maintains-buy-on-avidity-biosciences-raises-price-target-to-46

Needham analyst Joseph Stringer maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target from $35 t...

 chardan-capital-maintains-buy-on-avidity-biosciences-raises-price-target-to-45

Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target from $3...

 evercore-isi-group-maintains-outperform-on-avidity-biosciences-raises-price-target-to-45

Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price t...

 why-avidity-biosciences-shares-are-trading-higher-wednesday

The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy (FSHD) with delpacibart braxlosiran.

Core News & Articles
Market-Moving News for June 12th
06/12/2024 12:49:59

BMR: 56% | Beamr Says Its Cloud Solution Is Now Available In The Oracle Cloud Marketplace; Provides AI-Ready Video Processing S...

 avidity-reports-over-50-reduction-in-dux4-regulated-genes-in-phase-12-fortitude-trial-for-facioscapulohumeral-muscular-dystrophy

Avidity plans to accelerate the initiation of registrational cohorts in FORTITUDE™ trial Delpacibart braxlosiran (AOC 1020),...